U. Fasol

A Phase I Dose–Escalation Study of Regorafenib (BAY 73–4506), an Inhibitor of Oncogenic, Angiogenic, and Stromal Kinases, in Patients with Advanced Solid Tumors

Martin Büchert, Ulrike Fasol, Oliver Boix, 2012, Clinical Cancer Research.

DCE-MRI assessment of the effect of vandetanib on tumor vasculature in patients with advanced colorectal cancer and liver metastases: a randomized phase I study

J. Hennig, A. Ryan, M. Büchert, 2009, Journal of angiogenesis research.

Overhauser shift of the electron spin-resonance line of Si:P at the metal-insulator transition: II. 29Si contribution

U. Fasol, E. Dormann, 2002 .

Overhauser shift of the electron spin-resonance line of Si:P at the metal-insulator transition: I. Integral shift

U. Fasol, E. Dormann, 2001 .

[Oxygen-enhanced MRI of the lung: optimized calculation of difference images].

S. Schoenberg, M. Reiser, O. Dietrich, 2006, Der Radiologe.

Onset and maintenance of angiogenesis in biomaterials: in vivo assessment by dynamic contrast-enhanced MRI.

Jürgen Hennig, Ralf Gutwald, Rainer Schmelzeisen, 2009, Tissue engineering. Part C, Methods.

Phase I study of BAY 73-4506, an inhibitor of oncogenic and angiogenic kinases, in patients with advanced refractory colorectal carcinoma (CRC).

M. Büchert, D. Strumberg, M. Scheulen, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Vascular and pharmacokinetic effects of EndoTAG-1 in patients with advanced cancer and liver metastasis.

M. Büchert, U. Fiedler, K. Mross, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase I study of telatinib (BAY 57-9352): analysis of safety, pharmacokinetics, tumor efficacy, and biomarkers in patients with colorectal cancer

M. Büchert, D. Strumberg, M. Scheulen, 2011, Vascular cell.

Fast oxygen‐enhanced multislice imaging of the lung using parallel acquisition techniques

Konstantin Nikolaou, Olaf Dietrich, Christoph Losert, 2005, Magnetic resonance in medicine.

Phase I study of BAY 73–4506, an inhibitor of oncogenic and angiogenic kinases, in patients with advanced solid tumors: Final results of a dose-escalation study

C. Unger, D. Strumberg, M. Scheulen, 2008 .